Literature DB >> 31950242

Clinicopathologic analysis of upper urinary tract carcinoma with variant histology.

Inês Rolim1,2, Vanessa Henriques2, Nídia Rolim3, Ana Blanca4, Rita Canas Marques2, Metka Volavšek5, Inês Carvalho2, Rodolfo Montironi6, Alessia Cimadamore6, Maria R Raspollini7, Liang Cheng8, Antonio Lopez-Beltran9,10.   

Abstract

We report on the clinicopathologic features of 115 cases of high-grade urothelial carcinoma of the upper urinary tract with variant histology present in 39 (34%). Variant histology was typically seen in high pathological stage (pT2-pT4) (82%, 32 cases) patients with lower survival rate (70%, 27 cases, median survival 31 months) and consisted in urothelial with one (23%), two (3%), and three or more variants (3%); 4% of cases presented with pure variant histology. Squamous divergent differentiation was the most common variant (7%) followed by sarcomatoid (6%) and glandular (4%), followed by 3% each of micropapillary, diffuse-plasmacytoid, inverted growth, clear cell glycogenic, or lipid-rich. The pseudo-angiosarcomatous variant is seen in 2%, and 1% each of nested, giant-cell, lymphoepithelioma-like, small-cell, trophoblastic, rhabdoid, microcystic, lymphoid-rich stroma, or myxoid stroma/chordoid completed the study series. Loss of mismatch repair protein expression was identified in one case of upper urinary tract carcinoma with inverted growth variant (3.6%). Variant histology was associated to pathological stage (p = 0.007) and survival status (p = 0.039). The univariate survival analysis identified variant histology as a feature of lower recurrence-free survival (p = 0.046). Our findings suggest that variant histology is a feature of aggressiveness in urothelial carcinoma of the upper urinary tract worth it to be reported.

Entities:  

Keywords:  Divergent; Glandular; MMR; Micropapillary; Nested; Plasmacytoid; Renal pelvis; Sarcomatoid; Squamous; Ureter; Urothelial carcinoma; Variant histology

Year:  2020        PMID: 31950242     DOI: 10.1007/s00428-020-02745-4

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  6 in total

1.  Microcystic urothelial carcinoma: a case report.

Authors:  Mengyao Liu; Shuaichen Liu; Lei Bao; Weiyi Chen; Ping Yang; Huihui Zhou
Journal:  Int J Clin Exp Pathol       Date:  2020-11-01

2.  [Correlation between daily fluid intake behavioral habits and pathological characteristics of upper tract urothelial carcinoma].

Authors:  Z H Li; C R Xu; Y Liu; H Guan; M Zhang; X Y Che; Q Tang; Y B Huang; X S Li; L Q Hou
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2022-08-18

3.  Analysis of genetic profiling, pathomics signature, and prognostic features of primary lymphoepithelioma-like carcinoma of the renal pelvis.

Authors:  Bo Fan; Yuanbin Huang; Hongshuo Zhang; Tingyu Chen; Shenghua Tao; Xiaogang Wang; Shuang Wen; Honglong Wang; Zhe Lin; Tianqing Liu; Hongxian Zhang; Tao He; Xiancheng Li
Journal:  Mol Oncol       Date:  2022-09-02       Impact factor: 7.449

4.  Impact of Adjuvant Chemotherapy on Variant Histology of Upper Tract Urothelial Carcinoma: A Propensity Score-Matched Cohort Analysis.

Authors:  Chi-Wen Lo; Wei-Ming Li; Hung-Lung Ke; Yi-Huei Chang; Hsi-Chin Wu; I-Hsuan Alan Chen; Jen-Tai Lin; Chao-Yuan Huang; Chung-Hsin Chen; Jen-Shu Tseng; Wun-Rong Lin; Yuan-Hong Jiang; Yu-Khun Lee; Chung-You Tsai; Shiu-Dong Chung; Thomas Y Hsueh; Allen W Chiu; Yeong-Chin Jou; Ian-Seng Cheong; Yung-Tai Chen; Jih-Sheng Chen; Bing-Juin Chiang; Chih-Chin Yu; Wei Yu Lin; Chia-Chang Wu; Chuan-Shu Chen; Han-Yu Weng; Yao-Chou Tsai
Journal:  Front Oncol       Date:  2022-04-22       Impact factor: 5.738

5.  Upper Urinary Tract Urothelial Carcinoma With Squamous, Glandular, and Sarcomatoid Variants in a Horseshoe Kidney: A Novel Case Report and Literature Review.

Authors:  Jehad Fikri; Abdullah M Almalki; Sattam A Almalki; Muradi Murad; Sara Makhdoum; Fadil Hassan
Journal:  Cureus       Date:  2021-11-16

Review 6.  Unusual Faces of Bladder Cancer.

Authors:  Claudia Manini; José I López
Journal:  Cancers (Basel)       Date:  2020-12-10       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.